These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23016864)

  • 1. Fibroblast growth factor receptor inhibitors.
    Kumar SB; Narasu L; Gundla R; Dayam R; J A R P S
    Curr Pharm Des; 2013; 19(4):687-701. PubMed ID: 23016864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
    Brameld KA; Owens TD; Verner E; Venetsanakos E; Bradshaw JM; Phan VT; Tam D; Leung K; Shu J; LaStant J; Loughhead DG; Ton T; Karr DE; Gerritsen ME; Goldstein DM; Funk JO
    J Med Chem; 2017 Aug; 60(15):6516-6527. PubMed ID: 28665128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
    Dieci MV; Arnedos M; Andre F; Soria JC
    Cancer Discov; 2013 Mar; 3(3):264-79. PubMed ID: 23418312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK).
    Manetti F; Botta M
    Curr Pharm Des; 2003; 9(7):567-81. PubMed ID: 12570804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer molecules targeting fibroblast growth factor receptors.
    Liang G; Liu Z; Wu J; Cai Y; Li X
    Trends Pharmacol Sci; 2012 Oct; 33(10):531-41. PubMed ID: 22884522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
    Brooks AN; Kilgour E; Smith PD
    Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FGFR Signaling in Cancer.
    Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
    Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and screening studies of potent thiazol-2-amine derivatives as fibroblast growth factor receptor 1 inhibitors.
    Kumar BV; Lakshmi N; Kumar MR; Rambabu G; Manjashetty TH; Arunasree KM; Sriram D; Ramkumar K; Neamati N; Dayam R; Sarma JA
    Curr Top Med Chem; 2014; 14(17):2031-41. PubMed ID: 25322771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibition of fibroblast growth factor receptors in cancer.
    Liang G; Chen G; Wei X; Zhao Y; Li X
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
    Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
    Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development and ligand-protein interaction of small molecule anti-tumor FGFR inhibitors].
    Li XL; Qiu R; Li J; Hai L; Wu Y
    Yao Xue Xue Bao; 2016 Nov; 51(11):1689-97. PubMed ID: 29908111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
    Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
    Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.
    Rusnati M; Presta M
    Curr Pharm Des; 2007; 13(20):2025-44. PubMed ID: 17627537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
    St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
    Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.